{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:28:07Z","timestamp":1793395687799,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00983-3","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T17:33:30Z","timestamp":1754415210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Integrative genomic and bioinformatic prioritization of drug repurposing candidates for prostate cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Lalu Muhammad","family":"Irham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wirawan","family":"Adikusuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arief Rahman","family":"Afief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabiah","family":"Khairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rockie","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syarifatul","family":"Mufidah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmat Dani","family":"Satria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eko","family":"Mugiyanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darmawi","family":"Darmawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danang Prasetyaning","family":"Amukti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brilliant Citra","family":"Wirsahada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrina Theda","family":"Philothra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indra","family":"Jaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"983_CR1","doi-asserted-by":"crossref","unstructured":"Yuan F, Zhou Y, Wang M, Yang J, Wu K, Lu C, Kong X, Cai YD. Identifying new candidate genes and chemicals related to prostate cancer using a hybrid network and shortest path approach. Comput Math Methods Med. 2015:462363.","DOI":"10.1155\/2015\/462363"},{"key":"983_CR2","doi-asserted-by":"publisher","first-page":"103190","DOI":"10.1016\/j.jri.2020.103190","volume":"142","author":"JAF Silva","year":"2020","unstructured":"Silva JAF, Calmasini F, Siqueira-Berti A, Moraes-Vieira PMM, Quintar A, Carvalho HF. Prostate immunology: A challenging puzzle. J Reprod Immunol. 2020;142:103190.","journal-title":"J Reprod Immunol"},{"issue":"3","key":"983_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1159\/000442045","volume":"8","author":"H Mandaliya","year":"2015","unstructured":"Mandaliya H, Sung J, Hill J, Samali R, George M. Prostate cancer: cases of rare presentation and rare metastasis. Case Rep Oncol. 2015;8(3):526\u20139.","journal-title":"Case Rep Oncol"},{"key":"983_CR4","doi-asserted-by":"crossref","unstructured":"Szewczyk K, Jiang L, Khawaja H, Miranti CK, Zohar Y. Microfluidic applications in prostate cancer research. Micromachines (Basel). 2024;15(10).","DOI":"10.3390\/mi15101195"},{"issue":"14","key":"983_CR5","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/pros.24204","volume":"81","author":"Y Cao","year":"2021","unstructured":"Cao Y, Zhang W, Li Y, Fu J, Li H, Li X, Gao X, Zhang K, Liu S. Rates and trends in stage-specific prostate cancer incidence by age and race\/ethnicity, 2000\u20132017. Prostate. 2021;81(14):1071\u20137.","journal-title":"Prostate"},{"issue":"1","key":"983_CR6","first-page":"30","volume":"44","author":"SF Atekruse","year":"2017","unstructured":"Atekruse SF, Cosgrove C, Cronin K, Yu M. Comparing cancer registry abstracted and Self-Reported data on race and ethnicity. J Registry Manag. 2017;44(1):30\u20133.","journal-title":"J Registry Manag"},{"key":"983_CR7","doi-asserted-by":"publisher","first-page":"770500","DOI":"10.3389\/fonc.2021.770500","volume":"11","author":"JR Johnson","year":"2021","unstructured":"Johnson JR, Woods-Burnham L, Hooker SE Jr., Batai K, Kittles RA. Genetic contributions to prostate cancer disparities in men of West African descent. Front Oncol. 2021;11:770500.","journal-title":"Front Oncol"},{"issue":"1","key":"983_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12885-019-5440-8","volume":"19","author":"TKK Mamidi","year":"2019","unstructured":"Mamidi TKK, Wu J, Hicks C. Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer. BMC Cancer. 2019;19(1):229.","journal-title":"BMC Cancer"},{"key":"983_CR9","doi-asserted-by":"crossref","unstructured":"Mondschein R, Bolton D, Clouston D, Dowty J, Kavanagh L, Murphy D, Scott P, Taylor RA, Thorne H. Novel germline mutations in a cohort of men with familial prostate cancer. Cancers (Basel). 2022;14(15).","DOI":"10.3390\/cancers14153623"},{"key":"983_CR10","doi-asserted-by":"crossref","unstructured":"Mamidi TKK, Wu J, Hicks C. Mapping the germline and somatic mutation interaction landscape in indolent and aggressive prostate cancers. J Oncol. 2019:4168784.","DOI":"10.1155\/2019\/4168784"},{"issue":"4","key":"983_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10689-024-00383-2","volume":"23","author":"RM Paranal","year":"2024","unstructured":"Paranal RM, Wood LD, Klein AP, Roberts NJ. Understanding Familial risk of pancreatic ductal adenocarcinoma. Fam Cancer. 2024;23(4):419\u201328.","journal-title":"Fam Cancer"},{"key":"983_CR12","doi-asserted-by":"crossref","unstructured":"Irham LM, Adikusuma W, La\u2019ah AS, Chong R, Septama AW, Angelina M. Leveraging genomic and bioinformatic analysis to enhance drug repositioning for dermatomyositis. Bioeng (Basel). 2023;10(8).","DOI":"10.3390\/bioengineering10080890"},{"key":"983_CR13","first-page":"101334","volume":"32","author":"LM Irham","year":"2022","unstructured":"Irham LM, Adikusuma W, Perwitasari DA. Genomic variants-driven drug repurposing for tuberculosis by utilizing the established bioinformatic-based approach. Biochem Biophys Rep. 2022;32:101334.","journal-title":"Biochem Biophys Rep"},{"key":"983_CR14","first-page":"101307","volume":"31","author":"LM Irham","year":"2022","unstructured":"Irham LM, Adikusuma W, Perwitasari DA, Dania H, Maliza R, Faridah IN, Santri IN, Phiri YVA, Chong R. The use of genomic variants to drive drug repurposing for chronic hepatitis B. Biochem Biophys Rep. 2022;31:101307.","journal-title":"Biochem Biophys Rep"},{"issue":"4","key":"983_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/ng.2560","volume":"45","author":"RA Eeles","year":"2013","unstructured":"Eeles RA, Olama AAA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013;45(4):385\u201391.","journal-title":"Nat Genet"},{"issue":"4","key":"983_CR16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41391-022-00609-3","volume":"26","author":"F Marino","year":"2023","unstructured":"Marino F, Totaro A, Gandi C, Bientinesi R, Moretto S, Gavi F, Pierconti F, Iacovelli R, Bassi P, Sacco E. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine. Prostate Cancer Prostatic Dis. 2023;26(4):655\u201364.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"983_CR17","doi-asserted-by":"publisher","first-page":"1192792","DOI":"10.3389\/fonc.2023.1192792","volume":"13","author":"D Parker","year":"2023","unstructured":"Parker D, Zambelli J, Lara MK, Wolf TH, McDonald A, Lee E, Abou-Elkacem L, Gordon EJ, Baum RP. Case report: Long-term complete response to PSMA-targeted radioligand therapy and abiraterone in a metastatic prostate cancer patient. Front Oncol. 2023;13:1192792.","journal-title":"Front Oncol"},{"issue":"17\u201318","key":"983_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1101\/gad.315739.118","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018;32(17\u201318):1105\u201340.","journal-title":"Genes Dev"},{"issue":"12","key":"983_CR19","doi-asserted-by":"publisher","first-page":"E637","DOI":"10.5489\/cuaj.7173","volume":"15","author":"AC Zhang","year":"2021","unstructured":"Zhang AC, Rasul R, Golden A, Feuerstein MA. Incidence and mortality trends of metastatic prostate cancer: surveillance, epidemiology, and end results database analysis. Can Urol Assoc J. 2021;15(12):E637\u201343.","journal-title":"Can Urol Assoc J"},{"key":"983_CR20","doi-asserted-by":"publisher","first-page":"911101","DOI":"10.3389\/fgene.2022.911101","volume":"13","author":"C Samtal","year":"2022","unstructured":"Samtal C, El Jaddaoui I, Hamdi S, Bouguenouch L, Ouldim K, Nejjari C, Ghazal H, Bekkari H. Review of prostate cancer genomic studies in Africa. Front Genet. 2022;13:911101.","journal-title":"Front Genet"},{"key":"983_CR21","doi-asserted-by":"crossref","unstructured":"Vieira GM, Gellen LPA, da Veiga Borges Leal DF, Pastana LF, Vinagre L, Aquino VT, Fernandes MR, de Assump\u00e7\u00e3o PP, Burbano RMR, Dos Santos SEB, et al. Correlation between genomic variants and worldwide epidemiology of prostate cancer. Genes (Basel). 2022;13(6).","DOI":"10.3390\/genes13061039"},{"issue":"1","key":"983_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nrurol.2013.266","volume":"11","author":"R Eeles","year":"2014","unstructured":"Eeles R, Goh C, Castro E, Bancroft E, Guy M, Al Olama AA, Easton D, Kote-Jarai Z. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol. 2014;11(1):18\u201331.","journal-title":"Nat Rev Urol"},{"key":"983_CR23","first-page":"2001","volume":"2025","author":"J Huang","year":"2025","unstructured":"Huang J, Li Z, Lin Y. Identifying potential drug targets for prostate cancer from a genetic perspective: A Mendelian randomization study. MedRxiv. 2025;2025:2001\u20132. 25319933.","journal-title":"MedRxiv"},{"key":"983_CR24","doi-asserted-by":"crossref","unstructured":"Le TK, Duong QH, Baylot V, Fargette C, Baboudjian M, Colleaux L, Ta\u00efeb D, Rocchi P. Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments. Cancers (Basel). 2023;15(20).","DOI":"10.3390\/cancers15205047"},{"issue":"1","key":"983_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrurol.2015.254","volume":"13","author":"S Narayanan","year":"2016","unstructured":"Narayanan S, Srinivas S, Feldman D. Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. Nat Rev Urol. 2016;13(1):47\u201360.","journal-title":"Nat Rev Urol"},{"key":"983_CR26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ebiom.2019.03.009","volume":"42","author":"B Turanli","year":"2019","unstructured":"Turanli B, Zhang C, Kim W, Benfeitas R, Uhlen M, Arga KY, Mardinoglu A. Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning. EBioMedicine. 2019;42:386\u201396.","journal-title":"EBioMedicine"},{"issue":"10","key":"983_CR27","doi-asserted-by":"publisher","first-page":"e1456","DOI":"10.1002\/mgg3.1456","volume":"8","author":"Y Quan","year":"2020","unstructured":"Quan Y, Zhang QY, Lv BM, Xu RF, Zhang HY. Genome-wide pathogenesis interpretation using a heat diffusion-based systems genetics method and implications for gene function annotation. Mol Genet Genomic Med. 2020;8(10):e1456.","journal-title":"Mol Genet Genomic Med"},{"issue":"12","key":"983_CR28","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/nbt.2749","volume":"31","author":"JC Denny","year":"2013","unstructured":"Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, Field JR, Pulley JM, Ramirez AH, Bowton E, et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol. 2013;31(12):1102\u201310.","journal-title":"Nat Biotechnol"},{"issue":"D1","key":"983_CR29","doi-asserted-by":"publisher","first-page":"D877","DOI":"10.1093\/nar\/gkv1340","volume":"44","author":"LD Ward","year":"2016","unstructured":"Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res. 2016;44(D1):D877\u2013881.","journal-title":"Nucleic Acids Res"},{"issue":"7488","key":"983_CR30","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature12873","volume":"506","author":"Y Okada","year":"2014","unstructured":"Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376\u201381.","journal-title":"Nature"},{"issue":"6","key":"983_CR31","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(6):1437\u2013e14521417.","journal-title":"Cell"},{"key":"983_CR32","doi-asserted-by":"publisher","first-page":"105203","DOI":"10.1016\/j.phrs.2020.105203","volume":"161","author":"LM Irham","year":"2020","unstructured":"Irham LM, Wong HS, Chou WH, Adikusuma W, Mugiyanto E, Huang WC, Chang WC. Integration of genetic variants and gene network for drug repurposing in colorectal cancer. Pharmacol Res. 2020;161:105203.","journal-title":"Pharmacol Res"},{"key":"983_CR33","doi-asserted-by":"publisher","first-page":"724277","DOI":"10.3389\/fimmu.2021.724277","volume":"12","author":"W Adikusuma","year":"2021","unstructured":"Adikusuma W, Irham LM, Chou WH, Wong HS, Mugiyanto E, Ting J, Perwitasari DA, Chang WP, Chang WC. Drug repurposing for atopic dermatitis by integration of gene networking and genomic information. Front Immunol. 2021;12:724277.","journal-title":"Front Immunol"},{"issue":"1","key":"983_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s43046-024-00245-z","volume":"36","author":"K Dave","year":"2024","unstructured":"Dave K, Patel D, Dave N, Jain M. Genomic strategies for drug repurposing. J Egypt Natl Canc Inst. 2024;36(1):35.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"9","key":"983_CR35","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2217\/pgs-2018-0036","volume":"19","author":"C Lippmann","year":"2018","unstructured":"Lippmann C, Kringel D, Ultsch A, L\u00f6tsch J. Computational functional genomics-based approaches in analgesic drug discovery and repurposing. Pharmacogenomics. 2018;19(9):783\u201397.","journal-title":"Pharmacogenomics"},{"key":"983_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.semcancer.2019.09.023","volume":"68","author":"C Mottini","year":"2021","unstructured":"Mottini C, Napolitano F, Li Z, Gao X, Cardone L. Computer-aided drug repurposing for cancer therapy: approaches and opportunities to challenge anticancer targets. Semin Cancer Biol. 2021;68:59\u201374.","journal-title":"Semin Cancer Biol"},{"key":"983_CR37","unstructured":"Blanker MH, Bangma CH. Presence of prostate cancer, but absence of active treatment. Ned Tijdschr Geneeskd. 2019;163."},{"issue":"1","key":"983_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"983_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/imj.12731","volume":"46","author":"AJ Lomax","year":"2016","unstructured":"Lomax AJ, Parente P, Gilfillan C, Livingston PM, Davis ID, Pezaro C. First, do no harm\u2019: managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer. Intern Med J. 2016;46(2):141\u20138.","journal-title":"Intern Med J"},{"issue":"1","key":"983_CR40","first-page":"159","volume":"15","author":"J Zhang","year":"2022","unstructured":"Zhang J, Sun J, Bakht S, Hassan W. Recent development and future prospects of molecular targeted therapy in prostate cancer. Curr Mol Pharmacol. 2022;15(1):159\u201369.","journal-title":"Curr Mol Pharmacol"},{"key":"983_CR41","doi-asserted-by":"publisher","first-page":"955925","DOI":"10.3389\/fphar.2022.955925","volume":"13","author":"T Jian","year":"2022","unstructured":"Jian T, Zhan Y, Hu K, He L, Chen S, Hu R, Lu J. Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. Front Pharmacol. 2022;13:955925.","journal-title":"Front Pharmacol"},{"issue":"3","key":"983_CR42","first-page":"949","volume":"26","author":"M Kong","year":"2021","unstructured":"Kong M, Li H, Yuan W, Mao L, Chen J. The role of Circ_PRKCI\/miR-24-3p in the metastasis of prostate cancer. J Buon. 2021;26(3):949\u201355.","journal-title":"J Buon"},{"issue":"10","key":"983_CR43","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.21037\/tcr-20-1858","volume":"9","author":"Y Li","year":"2020","unstructured":"Li Y, Li Q, Gu J, Qian D, Qin X, Li D. Exosomal prostate-specific G-protein-coupled receptor induces osteoblast activity to promote the osteoblastic metastasis of prostate cancer. Transl Cancer Res. 2020;9(10):5857\u201367.","journal-title":"Transl Cancer Res"},{"key":"983_CR44","doi-asserted-by":"publisher","first-page":"106637","DOI":"10.1016\/j.biocel.2024.106637","volume":"175","author":"M Chen","year":"2024","unstructured":"Chen M, Fu Z, Wu C. Tumor-derived Exosomal ICAM1 promotes bone metastasis of triple-negative breast cancer by inducing CD8\u2009+\u2009T cell exhaustion. Int J Biochem Cell Biol. 2024;175:106637.","journal-title":"Int J Biochem Cell Biol"},{"key":"983_CR45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/bs.acr.2020.02.002","volume":"148","author":"X Gao","year":"2020","unstructured":"Gao X, Leone GW, Wang H. Cyclin D-CDK4\/6 functions in cancer. Adv Cancer Res. 2020;148:147\u201369.","journal-title":"Adv Cancer Res"},{"key":"983_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.semcancer.2019.09.020","volume":"68","author":"B Turanli","year":"2021","unstructured":"Turanli B, Altay O, Bor\u00e9n J, Turkez H, Nielsen J, Uhlen M, Arga KY, Mardinoglu A. Systems biology based drug repositioning for development of cancer therapy. Sem Cancer Biol. 2021;68:47\u201358.","journal-title":"Sem Cancer Biol"},{"issue":"1","key":"983_CR47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pros.23446","volume":"78","author":"H Bonkhoff","year":"2018","unstructured":"Bonkhoff H. Estrogen receptor signaling in prostate cancer: implications for carcinogenesis and tumor progression. Prostate. 2018;78(1):2\u201310.","journal-title":"Prostate"},{"key":"983_CR48","doi-asserted-by":"publisher","first-page":"175883591881834","DOI":"10.1177\/1758835918818346","volume":"10","author":"A Matutino","year":"2018","unstructured":"Matutino A, Amaro C, Verma S. CDK4\/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Ther Adv Med Oncol. 2018;10:1758835918818346.","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"983_CR49","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","volume":"23","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome Inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23(3):630\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"983_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107\u201314.","journal-title":"N Engl J Med"},{"issue":"8","key":"983_CR51","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1210\/jc.2003-032058","volume":"89","author":"MR Smith","year":"2004","unstructured":"Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(8):3841\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"983_CR52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fendo.2019.00059","volume":"10","author":"E Krashin","year":"2019","unstructured":"Krashin E, Piekie\u0142ko-Witkowska A, Ellis M, Ashur-Fabian O. Thyroid hormones and cancer: A comprehensive review of preclinical and clinical studies. Front Endocrinol (Lausanne). 2019;10:59.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00983-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:56:48Z","timestamp":1757343408000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00983-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["983"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00983-3","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this study as it solely involved the analysis of data sourced from publicly accessible databases. No direct involvement with human subjects or collection of new personal information took place. The datasets used were previously gathered under appropriate ethical standards by the original data custodians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}